| Literature DB >> 30813117 |
Michael Oliffe1, Emma Thompson2, Jenny Johnston3, Dianne Freeman1, Hanish Bagga1, Peter K K Wong1,2.
Abstract
OBJECTIVES: Patients are often provided with medicine information sheets (MIS). However, up to 60% of patients have low health literacy. The recommended readability level for health-related information is ≤grade 8. We sought to assess the readability of MIS given to patients by rheumatologists in Australia, the UK and Canada and to examine Australian patient comprehension of these documents.Entities:
Keywords: health literacy; medication adherence; patient comprehension; readability; rheumatology
Mesh:
Substances:
Year: 2019 PMID: 30813117 PMCID: PMC6377552 DOI: 10.1136/bmjopen-2018-024582
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Inclusions and exclusions.
Readability scores for Australian Rheumatology Association Medicine Information Sheets
| Medication | Flesch Reading Ease | FORCAST grade level | FORCAST reader age (years) | Gunning Fog grade level | Gunning Fog reader age (years) | SMOG grade level | SMOG reader age (years) | Mean grade level† | Mean reader age† |
| Abatacept | 49 | 11.2 | 16–17 | 12.3 | 17–18 | 12.4 | 17–18 | 12.0 | 17.2 |
| Adalimumab | 46 | 11.2 | 16–17 | 12.7 | 17–18 | 12.8 | 17–18 | 12.2 | 17.2 |
| Allopurinol | 53 | 10.8 | 15–16 | 10.5 | 15–16 | 11.5 | 16–17 | 10.9 | 15.8 |
| Apremilast | 56 | 10.6 | 15–16 | 11.3 | 16–17 | 11.7 | 16–17 | 11.2 | 16.2 |
| Azathioprine | 50 | 10.7 | 15–16 | 11.6 | 16–17 | 12.2 | 17–18 | 11.5 | 16.5 |
| Bisphosphonates intravenous | 49 | 11.1 | 16–17 | 12.1 | 17–18 | 12.2 | 17–18 | 11.8 | 17.2 |
| Bisphosphonates oral | 49 | 11.2 | 16–17 | 12.2 | 17–18 | 12.3 | 17–18 | 11.9 | 17.2 |
| Bosentan | 59 | 10.4 | 15–16 | 11.0 | 16–17 | 11.5 | 16–17 | 11.0 | 16.2 |
| Certolizumab | 46 | 11.1 | 16–17 | 12.8 | 17–18 | 12.9 | 17–18 | 12.3 | 17.2 |
| Colchicine | 53 | 11.1 | 16–17 | 11.7 | 16–17 | 11.7 | 16–17 | 11.5 | 16.5 |
| Cyclophosphamide | 53 | 10.7 | 15–16 | 10.8 | 15–16 | 11.8 | 16–17 | 11.1 | 15.8 |
| Ciclosporin | 54 | 10.7 | 15–16 | 11.8 | 16–17 | 12.0 | 17–18 | 11.5 | 16.5 |
| Denosumab | 50 | 11.0 | 16–17 | 11.9 | 16–17 | 12.1 | 17–18 | 11.7 | 16.8 |
| Etanercept | 48 | 11.1 | 16–17 | 12.7 | 17–18 | 12.8 | 17–18 | 12.2 | 17.2 |
| Febuxostat | 54 | 10.7 | 15–16 | 10.8 | 15–16 | 11.7 | 16–17 | 11.1 | 15.8 |
| Golimumab | 48 | 11.1 | 16–17 | 12.8 | 17–18 | 12.8 | 17–18 | 12.2 | 17.2 |
| Hyaluronic acid | 51 | 11.1 | 16–17 | 11.8 | 16–17 | 11.9 | 16–17 | 11.6 | 16.5 |
| Hydroxychloroquine | 49 | 10.9 | 15–16 | 11.6 | 16–17 | 11.7 | 16–17 | 11.4 | 16.2 |
| Infliximab | 49 | 11.1 | 16–17 | 12.5 | 17–18 | 12.6 | 17–18 | 12.1 | 17.2 |
| Leflunomide | 54 | 10.7 | 15–16 | 11.6 | 16–17 | 12.2 | 17–18 | 11.5 | 16.5 |
| Methotrexate | 52 | 10.9 | 15–16 | 11.4 | 16–17 | 12.3 | 17–18 | 11.5 | 16.5 |
| Mycophenolate | 50 | 11.0 | 16–17 | 11.6 | 16–17 | 12.5 | 17–18 | 11.7 | 16.8 |
| NSAIDs | 58 | 10.6 | 15–16 | 11.0 | 16–17 | 11.3 | 16–17 | 11.0 | 16.2 |
| Prednisone | 51 | 10.9 | 15–16 | 11.2 | 16–17 | 11.9 | 16–17 | 11.3 | 16.2 |
| Rituximab | 48 | 11.3 | 16–17 | 12.3 | 17–18 | 12.5 | 17–18 | 12.0 | 17.2 |
| Sulfasalazine | 50 | 10.9 | 15–16 | 11.4 | 16–17 | 11.9 | 16–17 | 11.4 | 16.2 |
| Teriparatide | 49 | 10.9 | 15–16 | 11.6 | 16–17 | 12.1 | 17–18 | 11.5 | 16.5 |
| Tocilizumab | 47 | 11.1 | 16–17 | 12.0 | 17–18 | 12.5 | 17–18 | 11.9 | 17.2 |
| Tofacitinib | 46 | 11.1 | 16–17 | 12.1 | 17–18 | 12.2 | 17–18 | 11.8 | 17.2 |
| Ustekinumab | 54 | 10.8 | 15–16 | 11.5 | 16–17 | 12.0 | 17–18 | 11.4 | 16.5 |
| Mean | 50.8 | 10.9 | 11.8 | 12.1 | 11.6 | 16.6 | |||
| SD | 0.6 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 |
*Flesch Scale Value: very easy (90–100), easy (80–89), fairly easy (70–79), standard (60–69), fairly difficult (50–59), difficult (30–49), very confusing (0–29).
†Mean of FORCAST, Gunning Fog and SMOG scores.
FORCAST (named after the authors FORd, CAylor, STicht); NSAIDs, non-steroidal anti-inflammatory drugs; SMOG, Simple Measure Of Gobbledygook.
Word and sentence statistics for Australian Rheumatology Association Medicine Information Sheets
| Medication | No. of sentences | No. of difficult | Mean sentence length | Total no. of words | No. of complex† words |
| Abatacept | 133 | 8 (5%) | 12.1 | 1612 | 314 (19.5%) |
| Adalimumab | 125 | 11 (8.8%) | 12.6 | 1576 | 315 (20%) |
| Allopurinol | 124 | 10 (8.1%) | 12.2 | 1507 | 252 (16.7%) |
| Apremilast | 92 | 9 (9.8%) | 11.9 | 1095 | 184 (16.8%) |
| Azathioprine | 118 | 9 (7.6%) | 13 | 1539 | 273 (17.7%) |
| Bisphosphonates intravenous | 95 | 11 (11.6%) | 12.6 | 1199 | 217 (18.1%) |
| Bisphosphonates oral | 112 | 11 (9.8%) | 13 | 1456 | 277 (19%) |
| Bosentan | 107 | 11 (10.3%) | 11.4 | 1219 | 214 (17.6%) |
| Certolizumab | 125 | 12 (9.6%) | 13 | 1624 | 320 (19.7%) |
| Colchicine | 123 | 8 (6.5%) | 11.6 | 1426 | 260 (18.2%) |
| Cyclophosphamide | 118 | 12 (10.2%) | 12.4 | 1469 | 266 (18.1%) |
| Ciclosporin | 102 | 8 (7.8%) | 12.1 | 1235 | 227 (18.4%) |
| Denosumab | 110 | 10 (9.1%) | 12 | 1317 | 243 (18.5%) |
| Etanercept | 124 | 11 (8.9%) | 13.1 | 1621 | 321 (19.8%) |
| Febuxostat | 120 | 12 (10%) | 12.4 | 1484 | 255 (17.2%) |
| Golimumab | 123 | 12 (9.8%) | 12.9 | 1588 | 316 (19.9%) |
| Hyaluronic acid | 81 | 4 (4.9%) | 11.3 | 919 | 181 (19.7%) |
| Hydroxychloroquine | 87 | 9 (10.3) | 12 | 1046 | 184 (17.6%) |
| Infliximab | 138 | 13 (9.4%) | 13.1 | 1807 | 344 (19%) |
| Leflunomide | 111 | 10 (9%) | 12.9 | 1427 | 254 (17.8%) |
| Methotrexate | 156 | 20 (12.8%) | 13.4 | 2097 | 375 (17.9%) |
| Mycophenolate | 141 | 15 (10.6%) | 12.1 | 1712 | 334 (19.5%) |
| NSAIDs | 137 | 14 (10.2%) | 12.8 | 1750 | 266 (15.2%) |
| Prednisone | 128 | 12 (9.4%) | 13 | 1668 | 292 (17.5%) |
| Rituximab | 132 | 9 (6.8%) | 12.3 | 1627 | 318 (19.5%) |
| Sulfasalazine | 124 | 9 (7.3%) | 12.1 | 1497 | 276 (18.4%) |
| Teriparatide | 114 | 13 (11.4%) | 11.5 | 1310 | 238 (18.2%) |
| Tocilizumab | 130 | 12 (9.2%) | 12.7 | 1654 | 311 (18.8%) |
| Tofacitinib | 111 | 7 (6.3%) | 12 | 1336 | 249 (18.6%) |
| Ustekinumab | 114 | 8 (7%) | 12.3 | 1406 | 259 (18.4%) |
| Mean | 118.5 | 10.7 (9.0%) | 12.4 | 1474.1 | 271.2 (18.4%) |
| SD | 3.0 | 0.5 | 0.1 | 44.6 | 9.0 |
*Difficult sentence: ≥22 words.
†Complex word: ≥3 syllables.
NSAIDs, non-steroidal anti-inflammatory drugs.
Assessment of patient literal comprehension (n=95 patients)
| Age (years, mean ±SD) | 60.0±13.2 |
| Sex (F/M) | 71/24 |
| Highest level of education | no. (%) |
| ≤Year 10 | 39 (41) |
| Year 10–12 | 15 (16) |
| Subdegree, eg, TAFE, apprenticeship | 22 (23) |
| University degree | 19 (20) |
| Median total score (max=5) | 4 |
| No. with all correct answers (ie, 5/5) | no. (%) |
| Adalimumab | 9/21 (43) |
| MTX | 7/11 (63.6) |
| NSAIDs | 6/28 (21.4) |
| Prednisone | 10/11 (90.9) |
| Abatacept | 13/24 (54.2) |
MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; TAFE, technical and further education.
Figure 2Answers to NSAID questions.
Readability scores for Arthritis Research United Kingdom Medicine Information Sheets
| Medication | Flesch Reading Ease | FORCAST grade level | FORCAST reader age | Gunning Fog grade level | Gunning Fog reader age | SMOG grade level | SMOG reader age | Mean grade level † | Mean reader age† |
| Abatacept | 46 | 10.9 | 15–16 | 13.1 | 18–19 | 13.2 | 18–19 | 12.4 | 17.5 |
| Adalimumab | 47 | 11.1 | 16–17 | 12.1 | 17–18 | 12.5 | 17–18 | 11.9 | 17.2 |
| Bisphosphonates | 53 | 11.1 | 16–17 | 11.9 | 16–17 | 12.3 | 17–18 | 11.8 | 16.8 |
| Denosumab | 42 | 11.7 | 16–17 | 12 | 17–18 | 12.6 | 17–18 | 12.1 | 17.2 |
| Etanercept | 49 | 11 | 16–17 | 11.9 | 16–17 | 12.4 | 17–18 | 11.8 | 16.8 |
| Hydroxychloroquine | 41 | 11.2 | 16–17 | 12.5 | 17–18 | 12.5 | 17–18 | 12.1 | 17.2 |
| Leflunomide | 53 | 10.8 | 15–16 | 11.9 | 16–17 | 12.2 | 17–18 | 11.6 | 16.5 |
| Methotrexate | 51 | 10.8 | 15–16 | 12.1 | 17–18 | 12.4 | 17–18 | 11.8 | 16.8 |
| Prednisolone | 55 | 11.1 | 16–17 | 11.3 | 16–17 | 11.6 | 16–17 | 11.3 | 16.5 |
| Sulfasalazine | 48 | 10.8 | 15–16 | 11.9 | 16–17 | 12.2 | 17–18 | 11.6 | 16.5 |
| Mean | 48.5 | 11.1 | 12.1 | 12.4 | 11.8 | 16.9 | |||
| SD | 1.5 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
*Flesch Scale Value: very easy (90–100), easy (80–89), fairly easy (70–79), standard (60–69), fairly difficult (50–59), difficult (30– 49), very confusing (0–29).
†Mean of FORCAST, Gunning Fog and SMOG scores.
FORCAST (named after the authors FORd, CAylor, STicht); SMOG, Simple Measure Of Gobbledygook.
Readability scores for Canadian Medicine Information Sheets
| Medication | Flesch Reading Ease | FORCAST grade level | FORCAST reader age | Gunning Fog grade level | Gunning Fog reader age | SMOG grade level | SMOG reader age | Mean grade level† | Mean reader age† |
| Abatacept | 65 | 10 | 15–16 | 8.5 | 13–14 | 10.3 | 15–16 | 9.6 | 14.8 |
| Adalimumab | 61 | 10.1 | 15–16 | 9.8 | 14–15 | 10.2 | 15–16 | 10 | 15.2 |
| Bisphosphonates | 63 | 10.2 | 15–16 | 9.5 | 14–15 | 10 | 15–16 | 9.9 | 15.2 |
| Denosumab | 66 | 9.6 | 14–15 | 9.6 | 14–15 | 10 | 15–16 | 9.7 | 14.8 |
| Etanercept | 64 | 10.1 | 15–16 | 9.9 | 14–15 | 10.3 | 15–16 | 10.1 | 15.2 |
| Hydroxychloroquine | 72 | 8.8 | 13–14 | 8.4 | 13–14 | 9.5 | 14–15 | 8.9 | 13.8 |
| Leflunomide | 67 | 9.9 | 14–15 | 9.4 | 14–15 | 9.9 | 14–15 | 9.7 | 14.5 |
| Methotrexate | 66 | 9.8 | 14–15 | 9.5 | 14–15 | 10.1 | 15–16 | 9.8 | 14.8 |
| Prednisolone | 69 | 10.2 | 15–16 | 9.8 | 14–15 | 10.1 | 15–16 | 10 | 15.2 |
| Sulfasalazine | 68 | 9.3 | 14–15 | 9.1 | 14–15 | 9.7 | 14–15 | 9.4 | 14.5 |
| Mean | 66.1 | 9.8 | 9.4 | 10.0 | 9.7 | 14.8 | |||
| SD | 1.0 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 |
*Flesch Scale Value: very easy (90–100), easy (80–89), fairly easy (70–79), standard (60–69), fairly difficult (50–59), difficult (30–49), very confusing (0–29).
†Mean of FORCAST, Gunning Fog and SMOG scores.
FORCAST (named after the authors FORd, CAylor, STicht); SMOG, Simple Measure Of Gobbledygook.
Word and sentence statistics for (A) UK and (B) Canadian Medicine Information Sheets
| Drug | No. of sentences | No. of difficult* sentences | Mean sentence length (no. of words) | No. of words | No. of complex† words |
| (A) UK | |||||
| Abatacept | 66 | 18 (27%) | 17.1 | 1130 | 206 (18%) |
| Adalimumab | 71 | 10 (14%) | 15.3 | 1086 | 191 (18%) |
| Bisphosphonates | 36 | 10 (28%) | 15.7 | 566 | 92 (16%) |
| Denosumab | 8 | 2 (25%) | 14.4 | 115 | 22 (19%) |
| Etanercept | 81 | 16 (20%) | 15.8 | 1282 | 214 (17%) |
| Hydroxychloroquine | 60 | 13 (22%) | 15.3 | 916 | 159 (17%) |
| Leflunomide | 63 | 12 (19%) | 16.1 | 1016 | 157 (15%) |
| Methotrexate | 75 | 13 (17%) | 16.2 | 1212 | 193 (16%) |
| Prednisolone | 60 | 15 (25%) | 17 | 1020 | 131 (13%) |
| Sulfasalazine | 53 | 12 (23%) | 16.6 | 881 | 132 (15%) |
| Mean | 57.3 | 12.1 (21%) | 15.95 | 922.4 | 149.7 (16%) |
| SD | 6.7 | 1.4 | 0.3 | 109.6 | 18.7 |
| (B) Canadian | |||||
| Abatacept | 25 | 0 | 11.1 | 278 | 38 (14%) |
| Adalimumab | 31 | 0 | 11 | 341 | 47 (14%) |
| Bisphosphonates | 30 | 0 | 10 | 301 | 41 (14%) |
| Denosumab | 24 | 0 | 10.3 | 246 | 34 (14%) |
| Etanercept | 31 | 0 | 10.9 | 339 | 48 (14%) |
| Hydroxychloroquine | 21 | 0 | 9.3 | 195 | 23 (12%) |
| Leflunomide | 34 | 0 | 10 | 339 | 46 (14%) |
| Methotrexate | 32 | 0 | 11.2 | 357 | 47 (13%) |
| Prednisolone | 36 | 0 | 10.1 | 363 | 53 (15%) |
| Sulfasalazine | 21 | 0 | 10.4 | 218 | 27 (12%) |
| Mean | 28.5 | 0 | 10.43 | 297.7 | 40.4 (14%) |
| SD | 1.7 | 0.0 | 0.2 | 19.2 | 3.1 |
*Difficult sentence: ≥22 words.
†Complex word: ≥3 syllables.